<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients
Image Overlay - Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

October 7, 2020

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Therapeutics, Inc. announced that it has dosed the first patient in its phase II study of istaroxime in patients experiencing early cardiogenic shock. Early cardiogenic shock is one of two developmental programs for istaroxime, with the other program targeting acute heart failure, which is supported by positive phase IIOa and IIb trial results and a FDA Fast Track designation. Fast Track programs put an extra strain on clinical trials logistics, but Yourway is prepared for such challenges.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Media

Articles

Global Reach in Clinical Trials: Beyond Presence to True Execution

Open chat
Come chat with us!
Hello! How can I help you?